WMS Poster 2018: A study of risdiplam (RG7916) in babies with pre-symptomatic spinal muscular atrophy

Oct 03, 2018

RAINBOWFISH is an open-label, single-arm, multicenter clinical study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of risdiplam (RG7916) in asymptomatic infants, aged from birth to 6 weeks of age (at first dose) with genetically diagnosed SMA. RAINBOWFISH will provide data on the early administration of RG7916 alongside the ongoing FIREFISH, SUNFISH and JEWELFISH studies.

Current View

Receive this presentation and more content via email